SMAD2 and urinary bladder cancer: Our results suggest that AHSG antagonizes the TGF-β signaling pathway by inhibiting the phosphorylation of Smad2/3 protein, promotes the proliferation of bladder cancer cells and regulates the cell cycle, thereby promoting the progression of bladder cancer.